WO2019225847A1 - Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii - Google Patents

Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii Download PDF

Info

Publication number
WO2019225847A1
WO2019225847A1 PCT/KR2019/003131 KR2019003131W WO2019225847A1 WO 2019225847 A1 WO2019225847 A1 WO 2019225847A1 KR 2019003131 W KR2019003131 W KR 2019003131W WO 2019225847 A1 WO2019225847 A1 WO 2019225847A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
obesity
alcohol
water
Prior art date
Application number
PCT/KR2019/003131
Other languages
English (en)
Korean (ko)
Inventor
이계완
김도훈
박유화
Original Assignee
동국제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국제약 주식회사 filed Critical 동국제약 주식회사
Publication of WO2019225847A1 publication Critical patent/WO2019225847A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/208—Fungi extracts

Definitions

  • the present invention relates to a composition for reducing obesity or body fat, and more particularly, to a composition for preventing, treating and improving obesity comprising white kidney bean extract and agar mushroom extract as an active ingredient.
  • composition for preventing and treating obesity comprising the white kidney bean extract and the extract of Awi mushrooms may be used as a pharmaceutical composition and / or health functional food composition to include a pharmaceutically acceptable excipient and / or a food acceptable acceptable excipient. Can be used.
  • the World Health Organization has determined that obesity exceeds 30 kg / m 2 of body mass index, with abnormal or excessive fat accumulating in the adipose tissue to the point of harm to health.
  • Obesity is a disease caused by a combination of factors such as environmental, genetic, mental and endocrine factors. Coronary artery disease, hypertension, stroke, type 2 diabetes, dyslipidemia, Sleep apnea, lung disease, and cancer. Obesity is a high socioeconomic cost because it is directly involved in the increased mortality from these diseases.
  • the anti-obesity agents sold in Korea include Belvic (component Lorcaserin), Contrab (component Bupropion / Naltrexone), purimine (component Phentemine), Puring (component Phendimetrazine), and saccharin (Glucagon-Like Peptide 1).
  • Belvic component Lorcaserin
  • Contrab component Bupropion / Naltrexone
  • purimine component Phentemine
  • Puring component Phendimetrazine
  • saccharin Glucagon-Like Peptide 1
  • the ultimate treatment goal of obesity is to go beyond weight loss and to ameliorate and prevent the diseases associated with obesity. Therefore, anti-obesity drugs should be safer in 'long-term use' and have an advantage in managing various comorbid diseases.
  • side effects that are currently on the market, including dizziness, nausea, constipation, dry mouth and depression.
  • a total of 27 raw materials are sold on the market for functional foods related to body fat reduction.
  • Representative raw materials include Garcinia cambogia extract, complex extracts such as seaweed and wild mango seed extract.
  • Garcinia cambogia extract has undergone functional re-evaluation from the Ministry of Food and Drug Safety due to safety issues related to liver disease, and complex extracts such as seaweed are also lacking in human test results to prove their effectiveness.
  • the present invention is to provide a composition having little side effects and safe for the human body, and excellent in preventing obesity or reducing body fat, and a pharmaceutical or functional food containing the same.
  • the present invention provides an anti-obesity or body fat reduction composition containing the extract of white kidney beans and awi mushrooms as an active ingredient used as food ingredients.
  • the present invention also provides an anti-obesity or body fat-reducing medicine or health functional food comprising the anti-obesity or body fat-reducing composition.
  • the present invention provides a use of anti-obesity or body fat reduction by mixing a white kidney bean extract and a mushroom extract.
  • the composition of the present invention and a pharmaceutical or functional food containing the same have an excellent anti-obesity or body fat reduction effect.
  • FIG. 1 is a process chart showing a process for preparing a composition according to the present invention.
  • Figure 2 is a graph showing the ⁇ -amylase inhibition rate by mixing ratio of the anti-obesity composition according to the present invention using the ⁇ -amylase (amylase) inhibition test.
  • Figure 3 is a graph showing the lipase activity rate of the mixing ratio of the anti-obesity composition according to the present invention using a triglyceride lipase activity test.
  • Figure 4 is a graph showing the change in body fat according to the mixing ratio of the anti-obesity composition in a high fat diet-induced obesity model.
  • 5 is a graph showing the weight change according to the mixing ratio of the anti-obesity composition in the high fat diet-induced obesity model.
  • Figure 6 is a graph showing the change in weight measurement according to the dose of the anti-obesity composition after 8 weeks repeated administration in a high fat diet-induced obesity model by date and experimental groups, respectively.
  • Figure 7 is a graph showing the total fat, abdominal fat and subcutaneous fat change with respect to the change in body fat mass according to the dose of the anti-obesity composition after repeated administration for 8 weeks in a high-fat diet obesity model.
  • FIG. 8 is a graph showing the change in carbohydrate content in the feces according to the dose of the anti-obesity composition after 8 weeks repeated administration in a high fat diet-induced obesity model.
  • FIG. 9 is a graph showing triglyceride changes in the liver according to the dose of the anti-obesity composition after repeated 8-week administration in a high fat diet-induced obesity model.
  • the present inventors endeavored to obtain a composition having anti-obesity and body fat reduction effect among natural products which have been used and consumed for a long time, and confirmed that the mixed extract of white kidney beans and awi mushrooms has an excellent anti-obesity and body fat reduction effect.
  • the present invention has been completed.
  • the present invention relates to a composition for preventing, treating or improving obesity, including white kidney bean extract and agar mushroom extract as active ingredients.
  • the present invention relates to a composition for preventing, treating or improving obesity comprising an extract of a mixture of white kidney beans and awi mushroom as an active ingredient.
  • the anti-obesity or body fat reducing composition of the present invention can be obtained through conventional methods such as extraction, concentration and drying.
  • the extract may be obtained by extracting with water, alcohol (preferably 1 to 4 carbon straight chain or branched alcohol), or a mixture of water and alcohol.
  • the extract thus obtained may be obtained by further extraction with a nonpolar solvent such as hexane, dichloromethane, chloroform, or ethyl acetate.
  • the extract may be extracted by applying heat during extraction.
  • the extract is extracted by applying heat when extracting the extract.
  • the content ratio of the white kidney bean extract and the awi mushroom extract is 1: 1 to 1: 5 and 1: 1 to 5: 1, preferably 1: 1 to 5, based on the weight of the solid dried extract. : 1, more preferably 2: 1 to 4: 1.
  • the anti-obesity or body fat reducing composition of the present invention can be prepared in the form of pharmaceuticals and functional foods.
  • Pharmaceuticals and health functional foods may include pharmaceutically or pharmaceutically acceptable excipients or additives.
  • the pharmaceutical or functional food containing the anti-obesity or body fat reducing composition of the present invention may be a solid preparation or a liquid preparation.
  • Solid form preparations include, but are not limited to, tablets, capsules, granules, powders, transdermals, suppositories, and the like.
  • Solid form preparations may include excipients, binders, disintegrants, glidants, coatings and the like.
  • Liquid formulations include, but are not limited to, aqueous solutions, suspensions, emulsions, syrups, aerosols, or sterile injectable solutions, and can be prepared by adding suitable colorants, flavors, stabilizers, and the like.
  • tablets may be mixed with suitable pharmaceutically acceptable excipients (maltodextrin) and pharmaceutically acceptable suitable binders such as D-sorbitol powder, silicon dioxide, and pharmaceutically acceptable suitable glidants such as magnesium stearate. It can be prepared using a tablet press.
  • suitable pharmaceutically acceptable excipients maltodextrin
  • suitable binders such as D-sorbitol powder, silicon dioxide, and pharmaceutically acceptable suitable glidants such as magnesium stearate.
  • the anti-obesity or body fat reducing composition of the present invention may be administered as an oral, injectable, inhalant, etc., depending on the condition to be treated and the condition of the individual, but is not limited thereto. It may be formulated into a suitable formulation including non-toxic, pharmaceutically acceptable carriers, additives, and the like, commonly used according to the route of administration.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting agents, sweeteners, fragrances, and preservatives. have.
  • Formulations for parenteral administration include sterile aqueous solutions, suspensions, emulsions, and lyophilized preparations.
  • the composition has a daily dose of 1.5 g / day or less of an active ingredient based on animal test results.
  • the composition may be administered in an amount of 0.1 to 300mg / kg daily dose based on the active ingredient.
  • the dosage may vary depending on the patient's condition (age, weight, gender, etc.). If necessary, the total daily dose may be divided into one day for convenience.
  • the extract-containing composition was obtained as follows.
  • Purified water was added 3 to 10 times to 5 kg of white kidney beans dry powder, and extracted with stirring for 24 hours.
  • the extracted extract was filtered (No. 2 whatman, Maidstone, England) and the filtrate was concentrated under reduced pressure (rotary vacuum evaporator) to obtain an extract.
  • the extract was freeze-dried (PVTFD10R, ILSHIN, Daejeon, Korea) to finally obtain 1.07 kg white kidney bean extract powder.
  • Purified water was added 3 to 10-fold to 5 kg of the above-mentioned mushroom dry powder, and extracted with stirring at 80 ° C for 10 hours.
  • the prepared extract was filtered and the filtrate was concentrated under reduced pressure to obtain an extract.
  • Dextrin was added to the extract, followed by spray drying. Finally, 1.01 kg of Awi mushroom extract powder was obtained.
  • White kidney bean extract powder and awi mushroom extract powder were stored in a freezer at -20 ° C., respectively, and the extracts were used alone or in the following experiments.
  • ⁇ -amylase inhibitory activity was evaluated by measuring the amount of soluble starch decreased by the enzymatic reaction by the iodine reaction method.
  • Human saliva-derived ⁇ -amylase was dissolved in PBS (phosphate buffer) at a concentration of 20 units / ml, and soluble starch was used as a substrate of ⁇ -amylase in 1% concentration in PBS (phosphate buffer).
  • ⁇ -amylase inhibitor As a standard of the ⁇ -amylase inhibitor, it was dissolved in DMSO at a concentration of 100 ⁇ g / ml of acarbose, and compared with the extract.
  • test group was evaluated with white kidney bean extract powder, awi mushroom extract powder, mixed extract powder (1: 1 ⁇ 1: 5 and 1: 1 ⁇ 5: 1) group of white kidney bean and awi mushroom (concentration of mixed extract) Maintain 1.0 mg / ml).
  • acarbose was used.
  • Table 1 summarizes the composition and test procedure of the control group, test group, black 1 and 2.
  • composition of the Test Composition Control Extract test group Blank 1 Blank 2 ⁇ -amylase solution (20 units / ml) 10 ⁇ l 10 ⁇ l PBS buffer 290 ⁇ l 290 ⁇ l 300 ⁇ l 300 ⁇ l Inhibitors (White Kidney Bean and Agaric Mushroom Extract) - 50 ⁇ l - 50 ⁇ l Standard (Akaboz) DMSO Solution 50 ⁇ l - 50 ⁇ l - Free incubation (37 °C, 10 minutes) 1% Soluble Starch Solution 350 ⁇ l 350 ⁇ l 350 ⁇ l 350 ⁇ l 350 ⁇ l Incubation (37 °C, 10 minutes) I 2 solution (0.1% KI + 0.01% I 2 /0.05N HCl) 300 ⁇ l 300 ⁇ l 300 ⁇ l 300 ⁇ l 300 ⁇ l OD measurement (620nm)
  • the anti-obesity composition according to the present invention increased the ⁇ -amylase inhibitory activity as the ratio of white kidney beans extract powder increases.
  • Lipase is responsible for breaking down triglycerides.
  • Orlistat a typical obesity treatment, reduces the absorption of triglycerides and cholesterol in the body by irreversibly binding and inactivating lipases that degrade triglycerides. Triglycerides and cholesterol that are not degraded are excreted unchanged in feces.
  • Orlistat as a standard for the evaluation of triglyceride lipase (TGL) activity was dissolved in DMSO at a concentration of 100 ⁇ g / ml and compared with the extract.
  • 16 ⁇ l substrate mixture (5 ⁇ l of 120 mM Tauricholic acid solution + 1 M Enzyme Assay buffer (1 M NaH 2 PO 4 , 1 M NaCl, pH 7.0) 10 ul + 400 mM P-NPB (p-nitrophenyl butyrate) 1 ul) was added to each well (96well). plate). In each well, add 54 ul of standard orlistat-containing DMSO solution or 54 ul of extract (concentration 250 ⁇ g / ml). Absorbance is measured at 405 nm using a plate reader.
  • Enzyme (2 mg / ml TGL solution 10ul + 0.1% BSA buffer 20ul) was added to the wells and mixed, the light is blocked, and incubated at room temperature for 10 minutes. Absorbance is measured at 405 nm using a plate reader.
  • test group was evaluated using a group of white kidney bean extract powder, awi mushroom extract powder, a mixture of white kidney bean extract and awi mushroom extract (1: 1 to 1: 5 and 1: 1 to 5: 1) (single extract and The mixed extract concentrations should all be 250 ⁇ g / ml). Negative control groups do not contain extracts or test substances.
  • the anti-obesity composition according to the present invention increased the activity of triglyceride enzymes as the ratio of agaric mushrooms increased.
  • mice Thirty-three C57BL / 6J male mice, 8 weeks old, were acclimated for a week, followed by feeding a high fat diet (45% HFD (Research diet, D12451) pellet form-free diet) for 2 weeks to induce obesity.
  • a high fat diet 45% HFD (Research diet, D12451) pellet form-free diet
  • Negative and diet were freely fed and body fat mass and body weight were measured during the experiment.
  • the test dose was administered at 200 mg / kg.
  • the anti-obesity composition [Case 3] mixed extract the tendency to reduce the body fat mass and weight at 8 weeks compared to the high-fat diet group [Con (-)] was confirmed in Figures 4 and 5.
  • test group was divided into seven groups. In other words
  • Negative and diet were freely fed during the trial period, including: 1 body weight (measured at the start of anti-obesity composition administration, twice a week thereafter and on autopsy day), and 2 body fat (eight weeks after initiation of anti-obesity composition administration) Body fat mass measured by micro-CT (micro-CT)), 3 Carbohydrate content in feces (measured by ELISA analysis on the 8th week sample after anti-obesity composition administration), 4 TG (triglyceride) in liver tissue Changes were measured (analyzed by blood samples collected at 4, 6, 7, and 8 weeks after the start of the anti-obesity composition administration and at the time of autopsy).
  • composition and dose settings of each test group are shown in Table 2 below:
  • the general symptoms and health status were confirmed, and 84 animals having a weight gain of at least 10% compared to the normal diet were used for the test.
  • Body weights were measured on the day of administration of the anti-obesity composition, afterwards twice a week and on an autopsy day.
  • the induced control group (G2) showed a significant increase in total fat, abdominal fat and subcutaneous fat compared to the non-induced control. The results are shown in FIG. 7 (p ⁇ 0.001).
  • feces were collected by each breeding box once a week. Collected feces were stored in a cryogenic freezer (about -70 °C or less) until analysis, and analyzed by ELISA analysis for the samples 2 and 8 weeks after administration of the anti-obesity composition.
  • the induced control group (G2) showed a significant increase compared to the non-induced control group (G1) (p ⁇ 0.001), and the high dose anti-obesity composition group (G7) compared to the induced control group (G2). Showed a significant decrease. This is shown in FIG. 9 (p ⁇ 0.005).
  • the composition of the present invention is to provide a composition having a low side effect and safe for the human body, excellent in preventing obesity or reducing body fat, and a pharmaceutical or functional food containing the same.

Abstract

L'invention concerne une composition de réduction de graisse corporelle et anti-obésité comprenant un extrait de haricot navy et un extrait de pleurotus eryngii en tant que principes actifs.
PCT/KR2019/003131 2018-05-23 2019-03-18 Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii WO2019225847A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180058477A KR20190133482A (ko) 2018-05-23 2018-05-23 흰강낭콩 및 아위버섯 추출물을 함유하는 항비만 또는 체지방 감소용 조성물
KR10-2018-0058477 2018-05-23

Publications (1)

Publication Number Publication Date
WO2019225847A1 true WO2019225847A1 (fr) 2019-11-28

Family

ID=68615600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/003131 WO2019225847A1 (fr) 2018-05-23 2019-03-18 Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii

Country Status (2)

Country Link
KR (1) KR20190133482A (fr)
WO (1) WO2019225847A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341475B1 (ko) * 2013-05-16 2013-12-13 주식회사 소울네이처푸드 부작용 없이 건강하게 체중감량이 가능한 다이어트 식품 조성물 및 그 제조방법
KR101389955B1 (ko) * 2013-05-21 2014-04-30 주식회사 위즈코즈 리테일 체지방 감소 효과를 갖는 코팅 정제의 제조 방법
KR20150048698A (ko) * 2015-04-21 2015-05-07 경상북도 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증 예방 또는 치료용 조성물
KR20160141027A (ko) * 2015-05-27 2016-12-08 경상북도 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
KR101855005B1 (ko) * 2016-11-21 2018-05-04 최종철 흰강낭콩을 함유하는 기능성 곡류 제조 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341475B1 (ko) * 2013-05-16 2013-12-13 주식회사 소울네이처푸드 부작용 없이 건강하게 체중감량이 가능한 다이어트 식품 조성물 및 그 제조방법
KR101389955B1 (ko) * 2013-05-21 2014-04-30 주식회사 위즈코즈 리테일 체지방 감소 효과를 갖는 코팅 정제의 제조 방법
KR20150048698A (ko) * 2015-04-21 2015-05-07 경상북도 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증 예방 또는 치료용 조성물
KR20160141027A (ko) * 2015-05-27 2016-12-08 경상북도 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
KR101855005B1 (ko) * 2016-11-21 2018-05-04 최종철 흰강낭콩을 함유하는 기능성 곡류 제조 방법

Also Published As

Publication number Publication date
KR20190133482A (ko) 2019-12-03

Similar Documents

Publication Publication Date Title
WO2022050516A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d'elaeocarpus sylvestris en tant que principe actif
KR100847439B1 (ko) 낙석등 추출물을 함유하는 염증성 질환 예방 및 치료용약제
WO2015030283A1 (fr) Composition destinée à prévenir et traiter la fatigue liée au cancer contenant de la poudre de ginseng traitée ou de l'extrait de ginseng traité comprenant un constituant de ginsénoside amélioré
WO2018236011A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'une diminution de la fonction intestinale, comprenant un hydrolysat de pousses de bambou ou des pousses de bambou fermentées en tant que principe actif
WO2014025202A1 (fr) Composition pharmaceutique contenant un mélange d'extrait de zingiber officinale rosc et d'extrait de paeonia lactiflora pallas, destinée à prévenir ou à traiter les démences et les troubles cognitifs
WO2016076607A2 (fr) Composition pharmaceutique et aliment fonctionnel pour la santé, contenant un concentré de ginseng rouge avec un composé enrichi en composant k, pour la prévention et le traitement du symptôme de la stéatose hépatique d'origine non alcoolique
WO2021167168A1 (fr) Composition, contenant un extrait d'agastache rugosa et de réglisse en tant que principe actif, pour la prévention ou le traitement de maladies respiratoires provoquées par les particules fines
WO2020209690A1 (fr) Composition pharmaceutique contenant un extrait de noix sauvage, une fraction de celui-ci, ou une substance physiologiquement active dérivée de celui-ci en tant que principe actif, et ayant des effets d'inhibition de la production de produits finaux de glycation avancée et de décomposition de produits finaux de glycation avancée
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2020116862A1 (fr) Composition pharmaceutique contenant un extrait d'eau florale de lonicera japonica, utilisée dans la prévention ou le traitement d'une nfection à helicobacter pylori
WO2019225847A1 (fr) Composition anti-obésité ou de réduction de graisse corporelle comprenant un extrait de haricot navy et un extrait de pleurotus eryngii
WO2012064158A2 (fr) Composition comprenant des herbes médicinales fermentées pour le traitement du syndrome du côlon irritable
US20070036872A1 (en) Alpha-glucosidase activity inhibitor
WO2015026123A1 (fr) Composition contenant un composé monoacétyldiacylglycérol comme principe actif pour la prévention ou le traitement de maladies pulmonaires obstructives chroniques
WO2023080409A1 (fr) Composition de prévention ou de soulagement d'un trouble du sommeil, comprenant une poudre de graines de zizyphus et une poudre de fruits de rosae multiflorae
WO2009134036A2 (fr) Produit de fermentation de mycélium de champignon utilisant l'écorce d'acanthopanax comme substrat, utile pour prévenir et pour traiter une gastrite, et produit pharmaceutique contenant l'extrait dudit produit de fermentation
WO2018131780A1 (fr) Composition destinée à prévenir ou à traiter la gastrite ou l'ulcère gastroduodénal
WO2018052171A1 (fr) Composition de traitement du cancer gastrique, contenant un extrait de larmes de job, et son procédé d'extraction
WO2019054641A2 (fr) Composition permettant de prévenir et de traiter les troubles gastro-intestinaux comprenant une souche de lactobacillus plantarum
WO2024072125A1 (fr) Composition pour améliorer les effets secondaires provoqués par le traitement du cancer comprenant une souche de lactobacillus fermentum hem1036 en tant que principe actif
WO2023204364A1 (fr) Composition permettant la prévention, l'amélioration ou le traitement de maladies respiratoires allergiques comprenant un extrait d'alpinia officinarum hance en tant que principe actif
WO2022131776A1 (fr) Composition pour la prévention ou le traitement de la colite, comprenant un extrait de pyrus ussuriensis ou un produit de fermentation de pyrus ussuriensis en tant que principe actif
WO2024085624A1 (fr) Composition de microbiome de surnageant de culture de fermentation de souche de bacillus velezensis kmu01 halophile ayant une efficacité anti-obésité
WO2017061787A1 (fr) Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif
KR100773246B1 (ko) 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807328

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19807328

Country of ref document: EP

Kind code of ref document: A1